Fig. 2: Kaplan–Meier plots for disease-free survival in patients with stage II/III CRC according to BRAF mutation status.

Patients are grouped into (a) individuals with mucinous tumours, (b) individuals with tumours with a mucinous component and (c) individuals with non-mucinous tumours. WT wild-type, MUT mutated; *p < 0.050.